Colistin sodium methanesulfonate
- CAS No.
- 8068-28-8
- Chemical Name:
- Colistin sodium methanesulfonate
- Synonyms
- Colistin Methanesulfonate;Colistimethate sodium CRS;COLISTIN SODIUM METHANESULFONATE;w1929;Promixi;colistinat;colimycinm;colymycinm;Coly-mycin M (TN);colistinsulfomethat
- CBNumber:
- CB1371673
- Molecular Formula:
- Unspecified
- Molecular Weight:
- 1749.82
- MOL File:
- 8068-28-8.mol
- Modify Date:
- 2025/4/29 15:35:11
| Melting point | >228°C (dec.) |
|---|---|
| storage temp. | 2-8°C |
| solubility | H2O: soluble10mg/mL |
| form | powder |
| color | white to faintly beige |
| PH | 6-8 (10mg/mL in H2O) |
| Water Solubility | Freely soluble in water |
| Merck | 13,2503 |
| CAS DataBase Reference | 8068-28-8 |
| EPA Substance Registry System | Colistimethate sodium (8068-28-8) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS08 |
|---|---|
| Signal word | Warning |
| Hazard statements | H362-H361 |
| Precautionary statements | P201-P260-P263-P264-P270-P308+P313-P201-P202-P281-P308+P313-P405-P501 |
| RIDADR | 3249 |
| WGK Germany | 2 |
| RTECS | GH1650000 |
| F | 3 |
| TSCA | Yes |
| HazardClass | 6.1(b) |
| PackingGroup | III |
| HS Code | 2941906000 |
| Toxicity | LD50 i.v. in mice: >550 mg/kg (Barnett) |
Colistin sodium methanesulfonate price More Price(5)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | C1511 | Colistin sodium methanesulfonate ~11,500?U/mg | 8068-28-8 | 10000000UNITS | ₹17406.6 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | PHR1737 | Colistimethate Sodium Pharmaceutical Secondary Standard; Certified Reference Material | 8068-28-8 | 500MG | ₹31652.3 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | C1511 | Colistin sodium methanesulfonate ~11,500?U/mg | 8068-28-8 | 100000000UNITS | ₹108293.3 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | 27655 | Colistin sodium methanesulfonate from Bacillus colistinus | 8068-28-8 | 1G | ₹8421.85 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | 27655 | Colistin sodium methanesulfonate from Bacillus colistinus | 8068-28-8 | 5G | ₹25904.23 | 2022-06-14 | Buy |
Colistin sodium methanesulfonate Chemical Properties,Uses,Production
Chemical Properties
White or almost white, hygroscopic powder.
Definition
ChEBI: A mixture where R = H or Me. Colistin in which each of the primary amino groups is converted to the corresponding aminomethanesulfonic acid sodium salt, commonly by the action of formaldehyde followed by sodium bisulfite. A polymyxin antibiotic derivative, it is used in the treatment of severe infections, particularly of multidrug-resistant Gram-negative bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii.
General Description
Two forms of colistins, colistin sulfate and colistin methanesulfonate sodium (Colistin sodium methanesulfonate)(CMS-Na), are commercially available. CMS-Na is administered intravenously, and CMS, the free base of CMS-Na consisting of CMS A and CMS B, is hydrolyzed in vivo to form active colistin A and colistin B6 . Colistin first became available for clinical use in 1959 and has been used worldwide for several decades[5].
Pharmacokinetics
Colistin is administered intravenously as the non-active prodrug, colistin methanesulfonate sodium (CMS). Colistin methanesulfonate sodium (Colistin sodium methanesulfonate) is eliminated mainly by renal clearance. If CMS is cleared rapidly by the kidney, less CMS is converted to colistin resulted in low colistin that could lead to ineffective antibacterial therapy. In patients with normal renal function (1–2 MIU of CMS), approximately 30–60% of a dose of CMS is converted to colistin. The renal clearance of CMS is much more efficient than the conversion of CMS to colistin. Therefore, to achieve a targeted concentration of >2 mg/L, patients must receive four to five times the amount of CMS. There was wide variability of colistin Cmax values (0.6–8.7 mg/L) in plasma among single-dose studies receiving 2–3 MIU of CMS in critically ill patients with preserved renal function. Almost none of the ICU patients achieved a colistin concentration of more than 2 mg/L in the Plachouras et al. and Mohamed et al. studies[4].
Safety Profile
Human poison by intramuscular route. Experimental poison by intramuscular, intraperitoneal, subcutaneous, and intravenous routes. Mildly toxic by ingestion. An experimental teratogen. Human systemic effects by intramuscular route: convulsions or effect on seizure threshold, change in motor activity, change in lrldney tubules, and urine volume decrease or anuria. Experimental reproductive effects. Used as an antibiotic. When heated to decomposition it emits very toxic fumes of NOx, SOx, and NazO
References
[1] Yusuf, Wan Nazirah Wan . "Population Pharmacokinetics of Colistin Methanesulfonate Sodium and Colistin in Critically Ill Patients: A Systematic Review." Pharmaceuticals 14(2021).
References
[1] nation r l, li j. colistin in the 21st century.[j]. current opinion in infectious diseases, 2009, 22(6): 535-543.
[2] bergen p j, li j, rayner c r, et al. colistin methanesulfonate is an inactive prodrug of colistin against pseudomonas aeruginosa.[j]. antimicrobial agents and chemotherapy, 2006, 50(6): 1953-1958.
[3] li j, turnidge j d, milne r w, et al. in vitro pharmacodynamic properties of colistin and colistin methanesulfonate against pseudomonas aeruginosaisolates from patients with cystic fibrosis[j]. antimicrobial agents and chemotherapy, 2001, 45(3): 781-785.
[4] Yusuf, Wan Nazirah Wan . "Population Pharmacokinetics of Colistin Methanesulfonate Sodium and Colistin in Critically Ill Patients: A Systematic Review."Pharmaceuticals14(2021).
[5] Mizuyachi, Kaori , et al. "Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects."Current Medical Research and Opinion27.12(2011):2261-2270.
Colistin sodium methanesulfonate Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Sumar biotech LLP | +91-9898272121 +91-9898272121 | Gujarat, India | 46 | 58 | Inquiry |
| PROVENTUS LIFE SCIENCES PVT. LTD. | +91 44 4740 0141 | New Delhi, India | 7 | 58 | Inquiry |
| Camus Pharma | 91-141-2229299 | Rajasthan, India | 46 | 58 | Inquiry |
| Novorix Pharma Pvt. Ltd. | 91--9849201334 | Hyderabad, India | 47 | 58 | Inquiry |
| Ralington Pharma | 91-79-48911722 | Gujarat, India | 312 | 58 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6257 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6739 | 58 | Inquiry |
| Sumar Biotech Llp | 08068970642Ext 388 | Gujarat, India | 12 | 58 | Inquiry |
| Pharma Affiliates | 172-5066494 | Haryana, India | 6754 | 58 | Inquiry |
| Glenmark Pharmaceuticals Limited | 91-22-40189999 | Maharashtra, India | 37 | 58 | Inquiry |
8068-28-8(Colistin sodium methanesulfonate)Related Search:
1of4
chevron_right